Standout Papers

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer 2004 2026 2011 2018 2.6k
  1. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer (2004)
    Thierry André, C. Boni et al. New England Journal of Medicine
  2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2012)
    Axel Grothey, Eric Van Cutsem et al. The Lancet
  3. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial (2009)
    Thierry André, C. Boni et al. Journal of Clinical Oncology
  4. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma (2011)
    Aleksandar D. Kostic, Dirk Gevers et al. Genome Research
  5. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study (2010)
    Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology
  6. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (2012)
    Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology
  7. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020)
    Guillem Argilés, Josep Tabernero et al. Annals of Oncology
  8. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (2017)
    Rodrigo Dienstmann, Louis Vermeulen et al. Nature reviews. Cancer
  9. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study (2015)
    Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology
  10. Development of PI3K inhibitors: lessons learned from early clinical trials (2013)
    Jordi Rodón, Rodrigo Dienstmann et al. Nature Reviews Clinical Oncology
  11. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials (2017)
    Dirk Arnold, B. Lueza et al. Annals of Oncology
  12. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer (2011)
    Daniel G. Haller, Josep Tabernero et al. Journal of Clinical Oncology
  13. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial (2015)
    David Goldstein, Robert H. El-Maraghi et al. JNCI Journal of the National Cancer Institute
  14. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer (2016)
    Sabine Tejpar, Sebastian Stintzing et al. JAMA Oncology
  15. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer (2021)
    Yelena Y. Janjigian, Akihito Kawazoe et al. Nature
  16. ESMO-Magnitude of Clinical Benefit Scale version 1.1 (2017)
    Nathan I. Cherny, Urania Dafni et al. Annals of Oncology
  17. Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors (2014)
    Rodrigo Dienstmann, Jordi Rodón et al. Molecular Cancer Therapeutics
  18. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study (2018)
    Josep Tabernero, Paulo M. Hoff et al. The Lancet Oncology
  19. Clinical management of metastatic colorectal cancer in the era of precision medicine (2022)
    Fortunato Ciardiello, Davide Ciardiello et al. CA A Cancer Journal for Clinicians
  20. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study (2021)
    Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology
  21. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (2018)
    Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology
  22. Current developments in gastric cancer: from molecular profiling to treatment strategy (2022)
    María Alsina, Virginia Arrazubi et al. Nature Reviews Gastroenterology & Hepatology
  23. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023)
    Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet
  24. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer (2023)
    Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine
  25. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial (2025)
    Scott Kopetz, Takayuki Yoshino et al. Nature Medicine

Immediate Impact

3 by Nobel laureates 11 from Science/Nature 110 standout
Sub-graph 1 of 21

Citing Papers

Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
Pan-cancer whole-genome comparison of primary and metastatic solid tumours
2023 StandoutNature
1 intermediate paper

Works of Josep Tabernero being referenced

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
2018

Author Peers

Author Last Decade Papers Cites
Josep Tabernero 33324 14187 14088 1.1k 49.1k
Heinz‐Josef Lenz 23991 9031 9427 856 34.9k
Salvatore Siena 26080 11832 7417 531 36.7k
Jaap Verweij 27869 21972 13557 619 54.4k
John D. Hainsworth 21144 12105 9981 623 36.4k
David Cunningham 41215 30035 12483 1.2k 76.0k
Armando Santoro 17399 13437 5502 903 33.7k
Razelle Kurzrock 24289 12014 20512 1.2k 58.6k
Fortunato Ciardiello 21501 11605 13119 626 33.5k
Scott Kopetz 19936 6578 7103 661 28.1k
Seth M. Steinberg 28549 13347 15293 861 57.6k

All Works

Loading papers...

Rankless by CCL
2026